May 14, 2020
SciMount announces FDA approval of SMP-100's IND application for the treatment of Irritable Bowel Syndrome
Mar 02, 2020
Heron Therapeutics Announces Financial Results for the Three and Twelve Months Ended December 31, 2019 and Highlights Recent Corporate Updates
Jan 13, 2020
Heron Therapeutics Highlights Progress in Pain Management and CINV Franchises
Nov 12, 2019
Heron Therapeutics Announces Financial Results for the Three and Nine Months Ended September 30, 2019 and Highlights Recent Corporate Updates
Oct 30, 2019
FDA Approves First Generic Version of Anti-Anxiety Medicine for Dogs
Aug 05, 2019
Heron Therapeutics Announces Financial Results for the Three and Six Months Ended June 30, 2019 and Highlights Recent Corporate Updates
Jul 10, 2019
AKYNZEO® Oral now covered by the Ontario, Quebec and Non-Insured Health Benefits public drugs plans
Jun 26, 2019
Breast Cancer Surgery: Avoiding-Minimizing Post-operative Nausea
Feb 22, 2019
Heron Therapeutics Announces Financial Results for the Three and Twelve Months Ended December 31, 2018 and Recent Corporate Progress
Feb 05, 2019
Heron Therapeutics Announces Retirement of Robert Rosen as President
Jan 07, 2019
Heron Therapeutics Highlights Progress in Pain Management and CINV Franchises
Nov 07, 2018
Heron Therapeutics Announces Financial Results for the Three and Nine Months Ended September 30, 2018 and Recent Corporate Progress
Sep 18, 2018
Chemotherapy-Induced Nausea & Vomiting (CINV) Treatment - Worldwide Markets to 2026: A $3.62 Billion Opportunity
Aug 08, 2018
Heron Therapeutics Announces Financial Results for the Three and Six Months Ended June 30, 2018 and Recent Corporate Progress
Jan 04, 2018
Acacia Pharma Announces FDA Acceptance of NDA Filing For BAREMSIS® for the Management of Post-operative Nausea & Vomiting